Heron Therapeutics (HRTX) Fundamental Analysis: Revenue, Earnings & Valuation

4.89 / 10

Netural

Fundamental analysis rates the stock neutral (4.9/10). Strengths include solid inventory turnover, low cost‑of‑sales ratio and healthy revenue growth. However, the long‑term debt‑to‑working‑capital ratio raises risk, and overall metrics suggest selective investment.

Analysis Checks(9/10)

Revenue-MV

Value0.11

Score3/3

Weight29.72%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value7.36

Score2/3

Weight0.41%

1M Return0.13%

Inventory turnover ratio

Value0.57

Score3/3

Weight-2.92%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value39.78

Score3/3

Weight5.52%

1M Return1.67%

PB-ROE

Value-0.29

Score2/3

Weight27.72%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value1.02

Score1/3

Weight-2.00%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.45%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value7.36

Score2/3

Weight0.17%

1M Return0.05%

Cost of sales ratio (%)

Value26.69

Score3/3

Weight0.86%

1M Return0.26%

Asset-MV

Value-0.55

Score2/3

Weight43.96%

1M Return11.12%

Is HRTX fundamentally strong?

HRTX scores 4.89/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -13.04% net margin, -7.46 P/E ratio, 10.51 P/B ratio, and -33.33% earnings growth, these metrics solidify its Netural investment rating.